| 扶正抗岩方联合吉非替尼治疗气虚血瘀型非小细胞肺癌(Ⅳ期)的前瞻性、平行随机、安慰剂对照临床研究 |
| |
| 引用本文： | 张一乐,陈麒,张炜.扶正抗岩方联合吉非替尼治疗气虚血瘀型非小细胞肺癌(Ⅳ期)的前瞻性、平行随机、安慰剂对照临床研究[J].上海中医药杂志,2019,53(3):37-41. |
| |
| 作者姓名： | 张一乐 陈麒 张炜 |
| |
| 作者单位： | 上海中医药大学附属曙光医院呼吸科 |
| |
| 基金项目： | 上海市科委上海中医临床重点实验室项目(14DZ2273200) |
| |
| 摘 要： | 目的观察扶正抗岩方联合吉非替尼治疗气虚血瘀型非小细胞肺癌(Ⅳ期)的临床疗效。方法将60例气虚血瘀型非小细胞肺癌(Ⅳ期)患者随机分为对照组与治疗组,每组30例。对照组予吉非替尼+中药安慰剂,治疗组予吉非替尼+扶正抗岩方。两组均服药至肿瘤进展而终止,观察比较近期疗效、远期疗效(无进展生存期)、KPS评分变化及不良反应情况。结果①试验期间,无病例脱落。②治疗组有效率、肿瘤控制率分别为53.33%、93.33%,对照组相应分别为43.33%、90.00%;组间近期疗效比较,差异无统计学意义(P0.05)。③组间无进展生存期比较,差异有统计学意义,治疗组明显长于对照组(P0.05)。④组间治疗后比较,治疗组KPS评分明显高于对照组(P0.05)。⑤两组不良反应比较,腹泻、恶心或呕吐发生情况等级差异有统计学意义,治疗组明显轻于对照组(P0.05)。结论扶正抗岩方联合吉非替尼治疗气虚血瘀型非小细胞肺癌(Ⅳ期),可以明显延长患者的无进展生存期,改善其生活质量,减轻EGFR-TKI药物的不良反应。
|
| 关 键 词： | 非小细胞肺癌 气虚血瘀证 扶正抗岩方 吉非替尼 分子靶向药物 无进展生存期 |
| 收稿时间： | 2018/10/18 0:00:00 |
A prospective, parallel, random, placebo-controlled clinical study on effects of Fuzheng Kangyan Formula combined with gefitinib on non-small cell lung cancer (stage IV) of qi deficiency and blood stasis type |
| |
| ZHANG Yile,CHEN Qi and ZHANG Wei.A prospective, parallel, random, placebo-controlled clinical study on effects of Fuzheng Kangyan Formula combined with gefitinib on non-small cell lung cancer (stage IV) of qi deficiency and blood stasis type[J].Shanghai Journal of Traditional Chinese Medicine,2019,53(3):37-41. |
| |
| Authors: | ZHANG Yile CHEN Qi and ZHANG Wei |
| |
| Institution: | Department of respiration, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China,Department of respiration, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China and Department of respiration, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China |
| |
| Abstract: | |
| |
| Keywords: | non-small cell lung cancer qi deficiency and blood stasis syndrome Fuzheng Kangyan Formula gefitinib molecular targeted agent progress-free survival |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《上海中医药杂志》浏览原始摘要信息 |
| 点击此处可从《上海中医药杂志》下载免费的PDF全文 |
|
